PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.
PepGen Inc. is offering common stock at $3.20 per share to raise up to $100,000,000 (approximately $115,000,000 if the underwriters exercise their 30-day option in full for an additional 4,687,500 shares). Underwriting discounts of $0.192 per share (about $6,000,000 without option, $6,900,000 with option) are disclosed. Net proceeds are earmarked primarily to fund the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and general corporate purposes, with management retaining broad discretion over final allocation. Lock-up agreements apply to certain holders and may be released early at the underwriters’ discretion. PepGen’s common stock trades on Nasdaq under PEPG. The company completed a November 23, 2020 reorganization that made PepGen Inc. the sole shareholder of PepGen Limited and adopted PepGen Limited’s historical financial statements. As of September 24, 2025, PepGen sold 1,000,000 shares under an at-the-market program for gross proceeds of $10 million.
PepGen Inc. is offering shares of common stock and pre-funded warrants as described in this prospectus supplement. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001, does not expire, and includes ownership limitations (default 4.99%, elective 9.99%, adjustable up to 19.99% after 61 days). The prospectus warns purchasers of immediate dilution and potential further dilution from future issuances or option exercises. Proceeds are stated to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and corporate purposes, though management retains broad discretion over allocation. The common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The document discloses underwriting arrangements, lock-up provisions, and U.S. and non-U.S. tax considerations for holders.
PepGen Inc. is offering shares of common stock and pre-funded warrants as described in this prospectus supplement. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001, does not expire, and includes ownership limitations (default 4.99%, elective 9.99%, adjustable up to 19.99% after 61 days). The prospectus warns purchasers of immediate dilution and potential further dilution from future issuances or option exercises. Proceeds are stated to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and corporate purposes, though management retains broad discretion over allocation. The common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The document discloses underwriting arrangements, lock-up provisions, and U.S. and non-U.S. tax considerations for holders.
PepGen Inc. is offering shares of common stock and pre-funded warrants as described in this prospectus supplement. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001, does not expire, and includes ownership limitations (default 4.99%, elective 9.99%, adjustable up to 19.99% after 61 days). The prospectus warns purchasers of immediate dilution and potential further dilution from future issuances or option exercises. Proceeds are stated to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and corporate purposes, though management retains broad discretion over allocation. The common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The document discloses underwriting arrangements, lock-up provisions, and U.S. and non-U.S. tax considerations for holders.
PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.
PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.
PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.
PepGen Inc. schedules a passive ownership disclosure showing Suvretta Capital Management, Averill Master Fund and Aaron Cowen each report shared beneficial ownership of 300,000 shares of PepGen common stock, equal to 0.9% of the class. The filing states the reporting persons have shared voting and shared dispositive power over those shares, and that the securities are directly owned by advisory clients of Suvretta Capital Management. The report also states no reported holder is known to beneficially own more than 5% of the common stock and includes a disclaimer that reported persons disclaim beneficial ownership except for pecuniary interest. The filing affirms the securities were not acquired to influence control.